To compare the therapeutic benefit of taxane plus platinum as postoperative adjuvant chemotherapy in endometrial cancer to conventional doxorubicin plus cisplatin was the researcher’s goal for this study.
From November 24, 2006, to January 7, 2011, patients with high-risk stage I or II endometrial cancer or stage III or IV endometrial cancer that did not spread beyond the abdominal cavity and had a residual tumor of 2 cm or larger were enrolled in this multicenter, open-label, phase 3 randomized clinical study. The data was examined between March 15, 2017, and June 30, 2017. Every three weeks, eligible patients were randomly randomized (1:1:1) to receive 6 cycles of doxorubicin, 60 mg/m2, plus cisplatin, 50 mg/m2, on day 1; docetaxel, 70 mg/m2, plus cisplatin, 60 mg/m2, on day 1; or paclitaxel, 180 mg/m2, with carboplatin (area under the curve, 6.0 mg/mL min) on day 1. The major goal was to achieve progression-free survival. Secondary outcomes were overall survival, the incidence of adverse events, tolerability, and the status of lymph node dissection.
The median (SD) age of the 788 eligible patients was 59 years; 263 were allocated to doxorubicin plus cisplatin treatment, 263 to docetaxel plus cisplatin treatment, and 262 to paclitaxel plus carboplatin treatment. The number of patients who did not complete 6 cycles in the doxorubicin plus cisplatin group was 53 (20.1 %), 45 (17.1%) in the docetaxel plus cisplatin group, and 63 (24.0%) in the paclitaxel plus carboplatin group. The tolerability of these regimens did not differ significantly. There was no statistical difference in progression-free survival (doxorubicin plus cisplatin, 191; docetaxel plus cisplatin, 208; paclitaxel plus carboplatin, 187; P =.12) or overall survival (doxorubicin plus cisplatin, 217; docetaxel plus cisplatin, 223; paclitaxel plus carboplatin, 215; P =.67) after The 5-year progression-free survival rate for the doxorubicin plus cisplatin group was 73.3%, 79.0% for the docetaxel plus cisplatin group, and 73.9% for the paclitaxel plus carboplatin group, respectively, while the 5-year overall survival rates were 82.7%, 88.1%, and 86.1%.
Reference:jamanetwork.com/journals/jamaoncology/fullarticle/2728809?resultClick=1
